Moderna, Inc. (BVL:MRNAUS)
Peru · Delayed Price · Currency is PEN · Price in USD | Market Cap | 263.66B +691.0% |
| Revenue (ttm) | 7.61B -27.6% |
| Net Income | -10.76B |
| EPS | -27.34 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 197.28 |
| Day's Range | n/a |
| 52-Week Range | 27.29 - 197.28 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 5, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial numbers in USD Financial StatementsNews
Moderna Stock Slumps as Citi Says It's Time to Sell After 500% Rally This Year
Moderna's stock has been flying high lately. That has one group of analysts saying it's time to sell.
Moderna and Fair Isaac: The Best and Worst S&P 500 Stocks for the Third Quarter
Moderna stock has rallied since the company unveiled clinical updates to its cancer vaccine in collaboration with Merck in late August.
Wednesday's First Moves: MRNA Downgrade, BA Jet Contract, JBL Earnings
Citi downgraded Moderna (MRNA) following the stock's astronomical rally in recent weeks. Boeing (BA) pens a $20 billion deal with the U.S. Navy for its next generation fighter jets.
Moderna stock falls 6% in premarket: here's why
Moderna stock MRNA fell nearly 6% in premarket trading on Wednesday after Citi downgraded the biotech company to ‘Sell' from ‘Hold', citing concerns that its recent valuation is difficult to justify. ...
Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded It to Sell.
Citi downgrades Moderna to Sell from Hold, saying the data around its cancer vaccine, instimeran autogene, isn't enough to justify the valuation.
Moderna appoints Juan Andres as COO
Moderna (MRNA) announced the addition of a COO role to support the increasing scale and diversification of the Company. The new role comes as Moderna prepares for the potential launch…
Citi Downgrades Moderna Stock after 222% Rally, Calls Oncology Expectations “Unrealistic”
Citigroup downgraded Moderna, Inc. ($MRNA) from Neutral/High Risk to Sell/High Risk after the biotech stock’s sharp two-month rally, arguing that optimism around its cancer pipeline is now fully refle...
Citi tells investors it's time to sell Moderna after 600%-plus stock gains
Revenue and profit forecasts fail to justify the hype baked into Moderna's share price, according to Citi's analysts.
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled th...
Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
Juan Andres to Return to Moderna as Chief Operating Officer Jerh Collins to Retire Following Four Years of Leadership at Moderna CAMBRIDGE, MA / ACCESS Newswire / September 30, 2026 / Moderna, Inc. (N...
Moderna sinks 4% to $195.42 after Citi downgrades to Sell
05:50 EDT Moderna (MRNA) sinks 4% to $195.42 after Citi downgrades to Sell
Moderna downgraded to Sell from Neutral at Citi
Citi analyst Geoff Meacham downgraded Moderna (MRNA) to Sell from Neutral with a price target of $80, up from $60. The firm cites valuation for the downgrade with the shares…
Moderna CEO details approaches, plans with cancer vaccines, WSJ says
Moderna’s (MRNA) shares recent popped up after positive news to its therapeutic cancer vaccine, an industry the company originally steered clear of out of fear of becoming the company that…
Moderna CEO's Realistic Approach to Innovation
Moderna's share price popped in August on positive news about its therapeutic cancer vaccine to prevent melanoma from recurring. At Journal House, United Nations General Assembly yesterday, the Journa...
Moderna CEO's Surprising Comment Gives Clues About Where Drugmaker Is Going Next
Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been' just a Covid vaccine company.
Moderna rises as CEO calls company an ‘mRNA platform company’
Shares of Moderna (MRNA) were higher near noon after CEO Stephane Bancel said at the Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum that the company “has…
Moderna Transcript: Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
The forum highlighted a shift from a COVID-19 focus to a broad mRNA platform spanning vaccines, oncology, rare diseases, and autoimmune therapies. Key advances include intismeran's strong phase III results, expansion into new indications, and a robust pipeline supported by proprietary manufacturing and AI-driven R&D.
Moderna will reveal the data for its mRNA cancer vaccine next month. Here's why it matters.
One reason that analysts and doctors want to see the data is to better understand how well the personalized treatment works.
Why Is Moderna Stock (MRNA) Soaring Today, September 21?
Moderna shares ($MRNA) surged by more than 14% to about $176 on Monday afternoon. This came after the U.S. pharma and biotech firm announced a key update in a statement.
Moderna announces late-breaking data to be presented at ESMO Congress 2026
Moderna (MRNA) announced that three abstracts on intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, have been accepted for presentation at the European Society for M...
Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected for presentation at a Presidential Symposium Moderna to host an investor event v...
Moderna stock rises 8%: can it continue its cancer vaccine success rally?
Moderna (MRNA) stock continued to rise on Thursday as investors assessed positive late-stage results for the company's personalised mRNA cancer vaccine and a series of analyst upgrades and higher pric...